- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Confirma expands R&D, names exec
MR software developer Confirma has entered into a research agreement with the Robert M. Berk Magnetic Resonance Institute at the University of California, San Diego, to conduct MR research using the company's breast MR image processing and analysis
MR software developer Confirma has entered into a research agreement with the Robert M. Berk Magnetic Resonance Institute at the University of California, San Diego, to conduct MR research using the company's breast MR image processing and analysis package. The purpose of this agreement is to further evaluate the product, called CADstream, and assess its impact on breast MRI interpretation. The first study will focus on measuring the effect of CADstream processing on reader sensitivity and specificity.
The evolution of this product will be conducted under new corporate leadership. The company announced March 27 that Max Lyon had been appointed president and CEO. Lyon was most recently the president and CEO of LifeSpex, a development-stage company applying light-based technologies to early cancer detection. From 1998 to 2000, he was a founder, director, and CEO of NexCura (formerly Cancerfacts.com), a Web-based cancer management company. From 1988 to 1998, Lyon served as CEO and a director of Bard Diagnostics (formerly Bainbridge Sciences), a wholly owned subsidiary of C.R. Bard.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
